Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
MariMed Inc. (ticker: MRMD) is a U.S.-based, multi-state cannabis operator focused on the cultivation, production, and retail distribution of regulated cannabis products. The company operates within the legal cannabis industry, primarily in the United States, and generates revenue through a vertically integrated model that spans cannabis cultivation, manufacturing, wholesale distribution, and branded retail dispensaries.
MariMed’s core revenue drivers are its owned cannabis brands and retail operations, with a strategic emphasis on branded consumer packaged goods. The company positions itself as a brand-forward operator, leveraging in-house product development and manufacturing capabilities to supply both its own dispensaries and third-party retailers. Founded in 2011, MariMed initially operated as a cannabis management and consulting firm and transitioned over time into a plant-touching operator as state regulations evolved, ultimately consolidating ownership of licenses and assets across multiple states.
Business Operations
MariMed conducts business through integrated operations that include cultivation facilities, manufacturing labs, and dispensaries, generating revenue from retail sales, wholesale distribution, and brand licensing. Its primary operating segments include Cannabis Retail, Cannabis Cultivation, and Cannabis Product Manufacturing, with a strong emphasis on branded products such as edibles, concentrates, flower, and wellness-oriented formulations.
The company controls several well-known cannabis brands, including Betty’s Eddies, Nature’s Heritage, Bourne Baking Co., InHouse, and Kalm Fusion, which are distributed across MariMed-owned dispensaries and third-party retail channels. MariMed operates through wholly owned subsidiaries in each state and does not currently rely on international joint ventures, reflecting regulatory constraints on cross-border cannabis commerce.
Strategic Position & Investments
MariMed’s strategy centers on disciplined expansion within existing markets, operational efficiency, and scaling its branded product portfolio rather than rapid geographic expansion. Growth initiatives have included capacity expansions at cultivation and manufacturing facilities, brand extensions into new product categories, and selective acquisitions of cannabis licenses and operating assets.
Notable investments include the consolidation of previously managed entities into wholly owned subsidiaries, strengthening balance sheet control and margin capture. The company continues to invest in product innovation, including precision-dosed edibles and terpene-specific formulations, positioning itself within the premium and wellness-oriented segments of the cannabis market. Data inconclusive based on available public sources regarding material investments outside the U.S. cannabis sector.
Geographic Footprint
MariMed operates exclusively within the United States, with a presence in multiple regulated cannabis markets. Its headquarters are located in Massachusetts, and the company maintains operations in key states including Massachusetts, Illinois, Maryland, Ohio, Delaware, and Nevada, subject to state-specific licensing structures.
The company’s geographic strategy emphasizes limited-license states and markets with favorable supply-demand dynamics. MariMed does not report active international operations, as cannabis remains federally illegal in the U.S., constraining cross-border business activities and foreign investment exposure.
Leadership & Governance
MariMed is led by an experienced executive team with backgrounds in regulated industries, consumer packaged goods, and operational management. The leadership emphasizes compliance, cash flow generation, and brand equity development within tightly regulated markets.
Key executives include:
- Jon Levine – Chief Executive Officer
- Tim Shaw – Chief Financial Officer
- Ted Tifft – Chief Operating Officer
- Robert Fireman – Chief Development Officer
- Allison Crockett – Chief Marketing Officer
The company is governed by a board of directors responsible for strategic oversight, risk management, and regulatory compliance, with a stated focus on sustainable growth and shareholder value creation within the evolving U.S. cannabis regulatory framework.